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AMP-activated protein kinase (AMPK), whose activ-
ity is a critical determinant of cell health, serves
a fundamental role in integrating extracellular and
intracellular nutrient information into signals that
regulate various metabolic processes. Despite the
importance of AMPK, its specific roles within the
different intracellular spaces remain unresolved,
largely due to the lack of real-time, organelle-specific
AMPK activity probes. Here, we present a series of
molecular tools that allows for the measurement of
AMPK activity at the different subcellular localiza-
tions and that allows for the rapid induction of
AMPK inhibition. We discovered that AMPKa1,
not AMPKa2, was the subunit that preferentially
conferred spatial specificity to AMPK, and that inhi-
bition of AMPK activity at the mitochondria was suf-
ficient for triggering cytosolic ATP increase. These
findings suggest that genetically encoded molecular
probes represent a powerful approach for revealing
the basic principles of the spatiotemporal nature of
AMPK regulation.
INTRODUCTION
Cell health and growth are critically dependent on nutrients
such as glucose, fatty acids, and amino acids (Marshall, 2006).
50 AMP-activated protein kinase (AMPK) is an evolutionarily
conserved serine/threonine protein kinase that integrates nutrient
signaling pathways to organize energy homeostasis (Hardie et al.,
2012). Mammalian AMPK is a heterotrimeric complex that com-
prises a catalytic a (a1 and a2), a regulatory b (b1 and b2), and g(g1, g2, and g3) subunits, each of which is encoded by a different
gene (Shackelford and Shaw, 2009). Multiple physiological fac-
tors are known to activate AMPK through intracellular metabolic
perturbations, most of which increase intracellular AMP/ATP
and ADP/ATP ratios and result in allosteric binding of either
AMP or ADP to an AMPK g subunit (Xiao et al., 2011; Oakhill
et al., 2011). This conformational change of an AMPKcomplex fa-
cilitates the subsequent phosphorylation of Thr172 in the a sub-
unit by upstream kinases, such as LKB1 (Woods et al., 2003).
The same phosphorylation could occur through a different up-
stream molecule, such as calcium ions that activate CaMKKb
(Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005).
Befitting its role in maintaining energy homeostasis, AMPK
switches on catabolic pathways and concomitantly switches
off anabolic pathways (Hardie, 2007; Kahn et al., 2005). In addi-
tion, recent studies have revealed diverse roles for AMPK in
regulating various cellular functions, including cell growth, auto-
phagy, neuronal polarity, and gene transcription (Mihaylova and
Shaw, 2011). However, the mechanism by which AMPK assures
execution of different downstream functions remains to be
determined. One solution for a signaling molecule to achieve
multi-tasking within the differential cellular space is compart-
mentalization. Compartmentalization of the AMPK response
could occur at three levels: regulators, effectors, and AMPK it-
self. Indeed, an AMPK complex has differential localization dy-
namics. Specifically, AMPK shuttles between the nucleus and
cytosol in response to various physiological inputs (Kodiha
et al., 2007; Suzuki et al., 2007; Warden et al., 2001). Further-
more, several studies demonstrated that activated AMPK could
accumulate within specific compartments, including endomem-
brane structures (Mitchelhill et al., 1997; Oakhill et al., 2010),
several mitotic components (Vazquez-Martin et al., 2009),
cytosol and nucleus (Tsou et al., 2011), and the basal bodies of
primary cilia (Boehlke et al., 2010). Such compartmentalization
is known to be one of the properties of multi-task molecules,Cell Reports 11, 657–670, April 28, 2015 ª2015 The Authors 657
Figure 1. FRET Response of osABKAR in Differential Subcellular Compartment
(A) Schematic diagram of osABKAR. OsABKAR is composed of organelle-targeting sequence (OTS) CFP variant, Cerulean, FHA1 phospho-amino acid-binding
domain, AMPK substrate motif, and YFP variant cpVE172.
(B) The series of osABKAR. OsABKAR includes plasma membrane-specific ABKAR (PM-ABKAR), Golgi apparatus-specific ABKAR (Golgi-ABKAR), ER-specific
ABKAR (ER-ABKAR), mitochondria-specific ABKAR (Mito-ABKAR), lysosome-specific ABKAR (Lyso-ABKAR), cytoplasm-specific ABKAR (Cyto-ABKAR), and
nucleus-specific ABKAR (Nuc-ABKAR).
(C) Representative FRET image of osABKAR. Indicated osABKARwas transfected into eitherWTMEFs or DKOMEFs. (Top) Representative YFP images; (bottom)
representative pseudocolor images of FRET/CFP ratio show the FRET response. Scale bar represents 10 mm.
(legend continued on next page)
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as exemplified by an oncogene product, Ras (Bivona and Philips,
2003). There are also several dozens of AMPK substrates that
reside at distinct locations in cells and tissues (Hardie et al.,
2012).
Despite the accumulating observations of the spatially defined
AMPK regulation, the most conclusive evidence for the AMPK
compartmentalization requires methods that enable both moni-
toring and perturbing AMPK activities at distinct subcellular loca-
tions. Genetically encodable Fo¨rster resonance energy transfer
(FRET)-based reporters visualize dynamic posttranslational
modifications, such as phosphorylation of lipids and proteins
in living cells, without the need to lyse cells for biochemical char-
acterization (Antal and Newton, 2013; Zhang and Allen, 2007).
One example of these phosphorylation reporters is an AMPK
biosensor, with which AMPK activity in either cytoplasmic or
nuclear compartments was successfully visualized (Tsou et al.,
2011). However, it is still imperative to systematically monitor
AMPK activity at subcellular compartments, such as ER, mito-
chondria, Golgi apparatus, and lysosomes. Here we report an
improved AMPK biosensor that can selectively profile the kinase
dynamics at each subcellular location of living cells. Gaining
insights into causality of the observations on dynamic signal
regulation inevitably requires target perturbation with high
spatiotemporal precision. A common pharmacological inhibitor
for AMPK like Compound C can only generate global AMPK in-
hibition. We thus developed another set of genetically encoded
molecular tools based on a rationally designed AMPK inhibitor
peptide (AIP), enabling the first-ever perturbation of AMPK activ-
ity exclusively at individual organelles on a timescale of minutes.
With a complete panel of the molecular sensors and actuators,
we herein provide direct evidence of subcellularly compartmen-
talized AMPK signaling.
RESULTS
Design Principle of Biosensors that Illuminate
Subcellular Compartment-Specific AMPK Activity
We recently improved a previously reported AMPK biosensor
(Tsou et al., 2011) by replacing fluorescent proteins. This new
AMPK reporter named ABKAR for AMPK/BRSK activity reporter
features a 2-fold larger dynamic range compared to the original
one.We also thoroughly characterized the binding profile and re-
vealed that, in addition to LKB1 and CaMKKb, brain-specific ki-
nases (BRSK1/2) also can phosphorylate ABKAR. We thus used
non-neuronal cells lacking expression of BRSK1/2 in the present
study to focus on the AMPK signaling.
A salient feature of genetically encoded FRET reporters is
that they can be targeted to predefined locations by appending
the corresponding subcellular localization signals. Therefore, we(D) AMPK activity at each subcellular compartment. WT MEFs and DKO MEFs w
in DKOMEFs), Nuc-ABKAR (n = 49 inWTMEFs, n = 47 in DKOMEFs), PM-ABKAR
31 in DKOMEFs), ER-ABKAR (n = 39 inWTMEFs, n = 33 in DKOMEFs), Mito-ABK
n = 35 in DKOMEFs), Cyto-ABKAR (TA) (n = 10 inWTMEFs, n = 12 in DKOMEFs), N
29 inWTMEFs, n = 30 in DKOMEFs), Golgi-ABKAR (TA) (n = 28 inWTMEFs, n = 26
ABKAR (TA) (n = 20 in WTMEFs, n = 23 in DKOMEFs), or Lyso-ABKAR (TA) (n = 5
DKO MEFs ratio was calculated from three to four independent experiments. Da
tistically nonsignificant.applied this approach to probe AMPK regulation in different
subcellular compartments. Tomeasure AMPK activity at specific
subcellular compartments, we fused it to well-established signal
sequences for the cytosolic surface of the following organelles
(Figure 1A): plasma membrane, Golgi apparatus, ER, mitochon-
dria, and lysosome as well as cytosol and nucleus. Those
biosensors were collectively referred to as organelle-specific
ABKAR (osABKAR) (Figure 1B; Table S1). We ensured their spe-
cific localization by expressing these biosensors together with
the appropriate organelle markers in mouse embryonic fibro-
blasts (MEFs) (Figure S1). We confirmed that none of the osAB-
KAR constructs had adverse effects on organelle morphology
(Figure S1).
Visualization of Subcellular Compartment-Specific
AMPK Activity
To determine whether these AMPK biosensors changed FRET
signal in an AMPK-dependent manner, we transfected osAB-
KAR into either cells derived from AMPK catalytic a subunit-
null MEFs (DKO MEFs) (Laderoute et al., 2006) or genetically
matched wild-type MEFs (WT MEFs). Cyto-ABKAR, a cytosol-
specific AMPK biosensor, indicated that the FRET signal in
the cytosol was 1.11 ± 0.17-fold higher than that in DKO
MEFs (n = 50 in WT MEFs and n = 37 in DKO MEFs), whereas
in the nucleus there was no significant difference in the FRET
signal between WT MEFs and DKO MEFs, according to the nu-
clear-specific AMPK biosensor Nuc-ABKAR (1.04 ± 0.12-fold,
n = 49 in WT MEFs and n = 47 in DKO MEFs) (Figures 1C
and 1D).
To examine AMPK activity in other subcellular locations, we
measured the FRET signal at the plasma membrane, Golgi
apparatus, mitochondria, ER, and lysosome using the corre-
sponding osABKAR in WT and DKO MEFs (Figure 1C). Notably,
the FRET signal in each endomembrane compartment in WT
MEFs was considerably higher than that in DKO MEFs (plasma
membrane: 1.26 ± 0.27-fold, n = 41 in WT MEFs and n = 28 in
DKO MEFs; Golgi apparatus: 2.19 ± 0.88-fold, n = 45 in WT
MEFs and n = 31 in DKO MEFs; ER: 2.08 ± 0.32-fold, n = 39
in WT MEFs and n = 33 in DKO MEFs; mitochondria: 1.67 ±
0.54-fold, n = 47 in WT MEFs and n = 32 in DKO MEFs; lyso-
some: 1.66 ± 0.45-fold, n = 47 in WT MEFs and n = 35 in
DKO MEFs) (Figure 1D). We observed generally little to no cor-
relation between the FRET signal of osABKAR biosensors and
their expression level in the range we tested (0.52 < r < 0.28)
(data not shown). For these FRET measurements, we used an
objective lens that was maximally corrected for chromatic aber-
ration to avoid optical artifacts potentially generated at thin-
membrane structures. We also compared the FRET signals
between the WT and DKO MEFs to cancel out any possibleere transiently transfected with either Cyto-ABKAR (n = 50 in WT MEFs, n = 37
(n = 41 inWTMEFs, n = 28 in DKOMEFs), Golgi-ABKAR (n = 45 inWTMEFs, n =
AR (n = 47 inWTMEFs, n = 32 in DKOMEFs), Lyso-ABKAR (n = 47 inWTMEFs,
uc-ABKAR (TA) (n = 68 inWTMEFs, n = 59 in DKOMEFs), PM-ABKAR (TA) (n =
in DKOMEFs), ER-ABKAR (TA) (n = 17 inWTMEFs, n = 26 in DKOMEFs), Mito-
7 in WT MEFs, n = 21 in DKOMEFs). Subsequently FRET signal in WT MEFs to
ta are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. N.S., sta-
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Figure 2. AMPK Activity Dynamics at Each Subcellular Compartment in Response to Metabolic Perturbation
(A–G) WT MEFs transiently transfected with indicated osABKAR were incubated under metabolically perturbed conditions: glucose starvation or 10 mM 2-DG
treatment. The FRET/CFP ratio was measured at each indicated time point. Measured FRET/CFP ratio was normalized to the cells incubated with DMEM (time
point: 0 hr). Quantification was performed on three independent experiments. All data are presented as mean ± SD.
(A) AMPK activity dynamics in cytosol. WTMEFs expressing Cyto-ABKARwere analyzed at each time point: 0 hr, n = 63; DMEM 0.5 hr, n = 42; DMEM2 hr, n = 40;
DMEM4 hr, n = 40; glucose starvation 0.5 hr, n = 35; glucose starvation 2 hr, n = 37; glucose starvation 4 hr, n = 31; 2-DG 0.5 hr, n = 38; 2-DG 2 hr, n = 39; and 2-DG
4 hr, n = 37.
(B) AMPK activity dynamics in nucleus.WTMEFs expressing Nuc-ABKARwere analyzed at each time point: 0 hr, n = 65; DMEM 0.5 hr, n = 50; DMEM 2 hr, n = 40;
DMEM4 hr, n = 41; glucose starvation 0.5 hr, n = 34; glucose starvation 2 hr, n = 38; glucose starvation 4 hr, n = 44; 2-DG 0.5 hr, n = 44; 2-DG 2 hr, n = 43; and 2-DG
4 hr, n = 41.
(C) AMPK activity dynamics at plasma membrane. WT MEFs expressing PM-ABKAR were analyzed at each time point: 0 hr, n = 49; DMEM 0.5 hr, n = 31; DMEM
2 hr, n = 36; DMEM 4 hr, n = 32; glucose starvation 0.5 hr, n = 30; glucose starvation 2 hr, n = 34; glucose starvation 4 hr, n = 27; 2-DG 0.5 hr, n = 25; 2-DG 2 hr, n =
32; and 2-DG 4 hr, n = 34.
(legend continued on next page)
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variability generated from different signal sequences tagged to
individual osABKAR. Interestingly, the AMPK activity exhibited
heterogeneity even at each organelle (Figure 1C), which may
reflect potential regulation of AMPK activity even within the
same compartment. Despite our careful selection, we acknowl-
edge possibilities of imaging artifacts derived from chromatic
aberration may exist. More sophisticated microscopy together
with a series of experiments would be needed to extend the
breadth of exploration of the regulation of AMPK activity at indi-
vidual organelles. By measuring the ABKAR FRET values in the
presence of AMPK-dominant mutants, we confirmed that the
ABKAR sensors indeed respond to AMPK activity (see the Sup-
plemental Results).
To test whether the observed FRET signals originate from the
phosphorylation at a threonine residue within the AMPK sub-
strate motif, we made a series of osABKAR (TA) biosensors
whose threonine residue in the motif was replaced with alanine.
As with osABKAR, osABKAR (TA) specifically localized to the in-
tended compartments (Figure S1). However, unlike osABKAR,
osABKAR (TA) did not exhibit different FRET values between
WT and DKO MEFs (Figure 1D), verifying that the observed
compartment-specific ABKAR signals indeed reflect AMPK ac-
tivity, rather than non-specific physical artifacts.
Effect of Glucose Availability on AMPK Activity at
Membrane Compartments
To address if and how the high AMPK activity at the mem-
branes alters based on the availability of nutrients, we exam-
ined both localization and phosphorylation of endogenous
AMPK at the cytosolic and membrane compartments with or
without 2-deoxyglucose (2-DG), an AMPK activator by inhibit-
ing glycolysis (Figure S2A). In agreement with previous studies
(Mitchelhill et al., 1997; Oakhill et al., 2010), our fractionation
assay indicated that AMPK levels in the membrane compart-
ment were approximately 6-fold higher than the levels in the
cytosolic compartment in the absence of 2-DG (Figures S2B
and S2C). Although we did not observe detectable relocaliza-
tion of AMPK upon 2-DG addition (Figures S2B and S2C), we
did observe significantly more phosphorylated AMPK in the
membranes than in the cytosol (Figures S2B and S2D). These
results suggest that AMPK activity is maintained at a high level
in the membrane compartment by concentrating the enzymes
at the membranes, a feature not much affected by glucose
availability.(D) AMPK activity dynamics at Golgi apparatus. WT MEFs expressing Golgi-ABK
2 hr, n = 30; DMEM 4 hr, n = 30; glucose starvation 0.5 hr, n = 22; glucose starvatio
27; and 2-DG 4 hr, n = 28.
(E) AMPK activity dynamics at ER. WT MEFs expressing ER-ABKAR were analyz
DMEM4hr, n = 41; glucose starvation 0.5 hr, n = 37; glucose starvation 2 hr, n = 41
4 hr, n = 39.
(F) AMPK activity dynamics at mitochondria. WT MEFs expressing Mito-ABKAR w
n = 25; DMEM 4 hr, n = 38; glucose starvation 0.5 hr, n = 32; glucose starvation 2 h
and 2-DG 4 hr, n = 37.
(G) AMPK activity dynamics at lysosome. WT MEFs expressing Lyso-ABKAR we
n = 26; DMEM 4 hr, n = 29; glucose starvation 0.5 hr, n = 32; glucose starvation 2 h
and 2-DG 4 hr, n = 30.
(H) Differential AMPK activity at each subcellular compartment in response to m
*p < 0.05, **p < 0.01, ***p < 0.001. N.S., statistically nonsignificant.Measurement of Subcellular AMPK Activity in Response
to Metabolic Inhibition
We next examined whether osABKAR was able to report
endogenous AMPK activity at the subcellular compartment
level in response to metabolic perturbation. To address this
question, WT MEFs were cultured under a glucose-deprived
condition that obstructs the ATP-synthesizing processes,
which results in increased AMPK activity (Figure S2A). In the
cytosolic compartment, glucose starvation resulted in an in-
crease in the FRET signal within 30 min (1.70 ± 0.61-fold, n =
35) and sustained the signal over 4 hr (Figure 2A). On the other
hand, glucose starvation did not cause an increase in the FRET
signal in the nuclear compartment even after 4 hr (0.95 ± 0.19-
fold, n = 44) (Figure 2B). Probing outside the nuclear compart-
ment, we found that glucose starvation gave a distinctive
response within 30 min at the plasma membrane (1.12 ± 0.23-
fold, n = 30) (Figure 2C), Golgi apparatus (1.22 ± 0.36-fold, n =
22) (Figure 2D), and ER (1.13 ± 0.24-fold, n = 37) (Figure 2E).
In contrast, FRET signal at mitochondria did not change in
30 min (1.03 ± 0.25-fold, n = 32) nor at the 2-hr time point
(1.07 ± 0.23-fold, n = 29), but significantly increased after 4 hr
(1.34 ± 0.44-fold, n = 25) (Figure 2F). Similar to the mitochon-
dria, the FRET signal at the lysosomal compartment also did
not change within 30 min (1.05 ± 0.29-fold, n = 26), but
increased gradually after 2 hr (1.20 ± 0.23-fold, n = 30)
(Figure 2G).
We then looked into the effects of another metabolic perturba-
tion input, 2-DG. Western blot analysis revealed that AMPK
activity in cells treated with 10 mM 2-DG or cultured with
glucose-withdrawn conditions was almost identical, as indicated
by the phosphorylation level of acetyl-CoA carboxylase (ACC),
one of the downstream effectors of AMPK (Figures S3A and
S3B). In stark contrast, 2-DG treatment did not alter FRET signal
in nucleic compartment over 4 hr (1.02 ± 0.2-fold, n = 41) (Fig-
ure 2B). Similarly, FRET signal at the plasma membrane did
not change after 4 hr of 2-DG treatment (1.09 ± 0.34-fold, n =
34) (Figure 2C). At the Golgi apparatus, ER, and lysosome,
2-DG stimulation resulted in an immediate response of 1.38 ±
0.18-fold (n = 24), 1.11 ± 0.22-fold (n = 39), and 1.28 ± 0.3-fold
(n = 29), respectively, within 30 min, and the FRET signals were
maintained at subsequent time points (Figures 2D, 2E, and
2G). Mito-ABKAR showed a robust and sustained response of
1.14 ± 0.33-fold (n = 37) and 1.23 ± 0.34-fold (n = 37) to 2-DG af-
ter 2 and 4 hr, respectively (Figure 2F).AR were analyzed at each time point: 0 hr, n = 38; DMEM 0.5 hr, n = 29; DMEM
n 2 hr, n = 24; glucose starvation 4 hr, n = 23; 2-DG 0.5 hr, n = 24; 2-DG 2 hr, n =
ed at each time point: 0 hr, n = 47; DMEM 0.5 hr, n = 30; DMEM 2 hr, n = 30;
; glucose starvation 4 hr, n = 29; 2-DG 0.5 hr, n = 37; 2-DG 2 hr, n = 39; and 2-DG
ere analyzed at each time point: 0 hr, n = 33; DMEM 0.5 hr, n = 31; DMEM 2 hr,
r, n = 29; glucose starvation 4 hr, n = 25; 2-DG 0.5 hr, n = 33; 2-DG 2 hr, n = 37;
re analyzed at each time point: 0 hr, n = 39; DMEM 0.5 hr, n = 29; DMEM 2 hr,
r, n = 30; glucose starvation 4 hr, n = 30; 2-DG 0.5 hr, n = 32; 2-DG 2 hr, n = 27;
etabolic perturbation inputs. All analyzed data in Figure 2 were summarized.
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Figure 3. Glucose Starvation and 2-DG Treatment Does Not Affect Intracellular pH Level
(A) WT MEFs were transiently transfected with either Cyto-ABKAR or Cyto-ABKAR (TA), and then AMPK activity subsequently was measured in cytosol under
indicated condition after 30 min. D, DMEM; GS, glucose starvation; 2DG, 10 mM 2-DG. WT MEFs expressing either Cyto-ABKAR in DMEM (n = 37), in glucose-
starved DMEM (n = 46), and in the presence of 2-DG (n = 48) or Cyto-ABKAR (TA) in DMEM (n = 28), in glucose-starved DMEM (n = 8), and in the presence of 2-DG
(n = 19) were analyzed. Measured FRET/CFP ratio was normalized to the cells incubated with DMEM. Quantification was performed on three independent
experiments. Data are presented as mean ± SD.
(B) Intracellular pH level under the same condition as in (A) (DMEM, n = 46; 2-DG, n = 42; and glucose starvation, n = 39) was measured by pH biosensor in WT
MEFs.
(C) Intracellular pH level in WT MEFs was monitored by time-lapse imaging; 10 mM 2-DG and H+ ionophore were added at the indicated time point (n = 3).
(D) Intracellular pH level in WT MEFs was monitored by time-lapse imaging; fresh DMEM containing glucose and H+ ionophore were added at the indicated time
point (n = 9).
*p < 0.05. N.S., statistically nonsignificant.As expected, the FRET signal in each compartment was rather
stable whenWTMEFs were cultured in nutrient-abundant condi-
tions (i.e., DMEM conditions in Figure 2). Additionally, we ascer-
tained that the FRET signal in each compartment did not change
in DKO MEFs cultured in nutrient-rich or metabolic-perturbation
conditions during the experiments (Figures S3C–S3I). Further-
more, we confirmed that neither 2-DG treatment nor glucose
starvation resulted in changes in FRET signal in WT MEFs
expressing Cyto-ABKAR (TA) (Figure 3A). We also measured
intracellular pH under these conditions to find little to no pH
change after 30 min (Figure 3B) as well as during the 30 min (Fig-
ures 3C and 3D). Collectively, the observation of the distinct
FRET changes at different organelles indicates that AMPK activ-
ity under distinctive metabolic impediments is spatiotemporally662 Cell Reports 11, 657–670, April 28, 2015 ª2015 The Authorsdiverse and osABKAR was a faithful indicator of these real-
time events in each compartment by responding to AMPK-medi-
ated phosphorylation (Figure 2H).
Differential Kinase Activity of the AMPK a Subunit in
Each Subcellular Compartment
Different phenotypes have been observed between a1 and a2
knockout mice (Viollet et al., 2009), making us speculate the dif-
ference may arise from distinct roles of these AMPK subunits
and may underlie the observed spatially unique AMPK activity.
We therefore set out to determine whether AMPK a1 and a2 sub-
units were able to reconstitute AMPK activity at each subcellular
compartment in DKO MEFs. We first examined whether mChF-
fused AMPK a1 and a2 subunits maintain kinase activity. We
observed that both mChF-AMPK a1 and a2 subunits were diffu-
sive in cells (Figure S4A). ABKAR showed that 2-DG stimulation
resulted in a 1.62 ± 0.24-fold increase of FRET signal inWTMEFs
expressing mChF (n = 10), while no 2-DG-stimulated response
was observed in DKO MEFs expressing mChF (0.91 ± 0.25-
fold, n = 9) (Figures S4B and S4C). However, the response of
the biosensor in the cytosol of DKO MEFs expressing either
mChF-AMPK a1 or a2 subunit was similar to 2-DG stimulation
as the WT MEFs (a1: 1.41 ± 0.34-fold, n = 11; a2: 1.67 ± 0.52-
fold, n = 9) (Figures S4B and S4C), revealing that reconstituted
mChF-AMPK a1 and a2 subunits were functional. Interestingly,
the expression levels of mChF-AMPK a1 and mChF-AMPK a2
did not seem to affect the results within the range of protein
expression we tested (Figure S4D).
We then transiently transfected either mChF-AMPK a1 or a2 in
either WT MEFs or DKO MEFs, and measured FRET signals in
each compartment where basal AMPK activity in WT MEFs
was higher than that in DKO MEFs (Figure 1D). Both AMPK a1
and a2 subunits recovered FRET signal to almost equivalent de-
gree in the cytosolic compartment, as judged by Cyto-ABKAR
(Figure 4A). As was the case with the cytosol, FRET signals in
ER and mitochondria in DKO MEFs were recovered by the
expression of AMPK a subunits to the same degree (Figures
4D and 4E). Interestingly, reconstitution of AMPK a1, but not
the a2 subunit, recovered the FRET signal at the plasma mem-
brane (Figure 4B). The functional difference of AMPK a subunits
also was observed in the Golgi apparatus and lysosome, where
the FRET signal was increased significantly more by the AMPK
a1 subunit compared to the a2 subunit (Figures 4C and 4F).
There was not any appreciable difference in the expression
levels of the AMPK a1 and a2 subunits in each experiment
(data not shown). Taken together, these results indicate that
the FRET signal reported by osABKAR in each subcellular
compartment was dynamically changeable in an AMPK a sub-
unit-dependent manner. In addition, each of the AMPK a1 and
a2 subunits apparently has a distinctive territory despite their
overlapping functions.
Development of a Genetically Encoded AMPK Inhibitor
Peptide
Determining causality of the observed spatiotemporally dynamic
AMPK regulation necessitates organelle-specific perturbation
of AMPK activity. A small molecule, Compound C (6-[4-(2-Piper-
idin-1-ylethoxy) phenyl]-3-pyridin-4-ylpyrazolo [1,5-a]pyrimi-
dine), is currently the only known cell-permeable agent that
can inhibit AMPK in an ATP-competitive manner. Though useful
as a pan-AMPK inhibitor, Compound C cannot suppress AMPK
activity at specific subcellular compartments due to its high
diffusivity. Therefore, we developed a new genetically encoded
AMPK inhibitor peptide, termed AIP, which allows for the inhibi-
tion of AMPK activity at specific subcellular locations. The amino
acid sequence of AIP is similar to the substrate peptide used in
ABKAR (Figure 5A), and it contains an AMPK-recognition motif
with a phosphorylation site.
To examine whether AIP is able to inhibit AMPK activity, we
performed an in vitro AMPK activity assay, whereby a known
AMPK substrate peptide (HMRSAMSGLHLVKRR) was used
as a glutathione-S-transferase (GST) conjugate (GST-SAMS).As a result, AIP suppressed AMPK-mediated phosphorylation
of GST-SAMS peptide competitively in a concentration-depen-
dent manner, with an IC50 value of 76 mM (Figures 5B and 5C).
We next examined the inhibitory effect of AIP (TA) peptide,
whose phosphorylation site was replaced with Ala residue (Fig-
ure 5A). In vitro AMPK activity assay showed that the inhibitory
effect of AIP (TA) was lower than that of AIP (IC50 = 277 versus
76 mM), but efficiently suppressed AMPK activity at the high con-
centration (Figures 5B and 5C). We confirmed that AIP, but not
AIP (TA) peptide, was phosphorylated by AMPK (Figure S5A),
implying that, while AIP inhibits AMPK in a substrate-competitive
manner, AIP (TA) works in a pseudosubstrate-competitive
manner. The inhibitory effect of AIP was robust and reasonable,
but not as strong as that of a known AMPK inhibitor, Compound
C, whose IC50 was 3 mM when measured in the same in vitro
AMPK assay (Figure S5B).
Next, we compared inhibitory effects on AMPK activity gener-
ated by AIP and Compound C. As a result, we observed that the
inhibitory effect of mChF-fused AIP (mChF-AIP) and 40 mMCom-
pound C on AMPK activity at Golgi apparatus, for example, was
nearly equivalent in WTMEFs (21.4% ± 10.1% decrease, n = 11,
versus 21.1% ± 11.2% decrease, n = 9, respectively), as re-
ported by Golgi-ABKAR (Figure S5C). AMPK activity at Golgi
apparatus was synergistically inhibited in WT MEFs expressing
mChF-AIP in the presence of Compound C (34.1% ± 13.3%
decrease, n = 8) (Figure S5C).
To examine whether AIP suppresses AMPK signaling in the
presence of 2-DG, we performed time-lapse imaging with
Cos7 cells expressing ABKAR. Stimulation with 2-DG in cells ex-
pressing mChF resulted in a 51.2% ± 9.4% response after
15 min (n = 15) (Figures 5D and 5E). Notably, cells expressing
mChF-AIP did not respond to 2-DG treatment (6.2% ± 5.6%,
n = 10), indicating that mChF-AIP competitively attenuated
AMPK activity in the presence of 2-DG (Figures 5D and 5E). On
the other hand, mChF-AIP (TA) could not suppress 2-DG-
induced AMPK activation, as judged by ABKAR (47.4% ±
8.9%, n = 11) (Figure 5D). It is of note here that the expression
level of mChF-AIP was similar to mChF and mChF-AIP (TA)
(data not shown).
To exclude the possibility that the direct interaction of phos-
phorylated mChF-AIP with the FHA domain in ABKAR was the
cause of FRET signal reduction, WT MEFs were transfected
with phospho-mimic AIP peptide: mChF-AIP (TD) and mChF-
AIP (TE), whose phosphorylation site was replaced with Asp
and Glu, respectively (Figure S6A). All constructs showed a
diffuse localization pattern in the cytosol when expressed in
cells (Figure S6B). Among these three peptides, mChF-AIP
was the only one that suppressed AMPK activity in WT
MEFs, as judged by ABKAR (Figures S6C and S6D). To further
characterize the inhibitory effect of AIP, we transiently ex-
pressed mChF-AIP in WT MEFs, and then checked the phos-
phorylation status of endogenous ACC. mChF-AIP expression
efficiently suppressed 2-DG-induced AMPK activation, as de-
tected by the phosphorylation level of ACC (Figure 5F). As an
additional note, basal phosphorylation of ACC also was sup-
pressed to some extent. These results suggest that mChF-
AIP suppresses phosphorylation activity of AMPK in living
cells.Cell Reports 11, 657–670, April 28, 2015 ª2015 The Authors 663
Figure 4. Activity Difference of AMPK a Subunits at Each Subcellular Compartment
Indicated osABKARwas co-transfected with mChF (Cont), mChF-AMPK a1 subunit (a1), or mChF-AMPK a2 subunit (a2) into either WTMEFs or DKOMEFs, then
FRET/CFP ratio was measured under nutrient-surplus condition. Measured FRET/CFP ratio was normalized to theWTMEFs expressing mChF (WTMEFs-Cont).
Quantification was performed on three independent experiments. All data are presented as mean ± SD.
(A) Reconstituted AMPK activity in cytosol. AMPK activity in cytosol in cells expressing Cyto-ABKAR and eithermChF (WTCont, n = 56; DKOCont, n = 34), mChF-
AMPK a1 (WT a1, n = 38; DKO a1, n = 45), or mChF-AMPK a2 (WT a2, n = 57; DKO a2, n = 49) was analyzed.
(B) Reconstituted AMPK activity at plasma membrane. AMPK activity at plasma membrane in cells expressing PM-ABKAR and either mChF (WT Cont, n = 29;
DKO Cont, n = 16), mChF-AMPK a1 (WT a1, n = 20; DKO a1, n = 25), or mChF-AMPK a2 (WT a2, n = 33; DKO a2, n = 16) was analyzed.
(C) Reconstituted AMPK activity at Golgi apparatus. AMPK activity at Golgi apparatus in cells expressing Golgi-ABKAR and either mChF (WT Cont, n = 33; DKO
Cont, n = 27), mChF-AMPK a1 (WT a1, n = 33; DKO a1, n = 31), or mChF-AMPK a2 (WT a2, n = 34; DKO a2, n = 31) was analyzed.
(D) Reconstituted AMPK activity at ER. AMPK activity at ER in cells expressing ER-ABKAR and either mChF (WTCont, n = 48; DKOCont, n = 36), mChF-AMPK a1
(WT a1, n = 55; DKO a1, n = 47), or mChF-AMPK a2 (WT a2, n = 43; DKO a2, n = 33) was analyzed.
(legend continued on next page)
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Perturbation of AMPK Signaling at Specific Subcellular
Compartments
Next, we assessed the functionality of AIP as an AMPK inhibitor.
Defective AMPK signaling leads to an increase of intracellular
ATP level in an mTORC1-dependent or -independent manner
(Faubert et al., 2013). In agreement with this, we also observed
that the concentration of intracellular ATP in DKO MEFs was
1.18 ± 0.28-fold higher than that in WT MEFs, as judged by the
ATP biosensor (Imamura et al., 2009; Figure 6A). To examine
whether AIP is able to mimic this phenotype, we expressed
mChF, mChF-AIP, or mChF-AIP (TA) in cells. As a result, the
mChF-AIP expression increased intracellular ATP in WT MEFs
(1.23 ± 0.29-fold, n = 29) compared to the cells expressing
mChF (Figure 6B). The expression of mChF-AIP (TA) did not alter
intracellular ATP in WT MEFs (1.05 ± 0.24-fold, n = 20) (Fig-
ure 6B). We also confirmed that expression of mChF-AIP did
not change intracellular ATP in DKO MEFs, as reported by the
ATP biosensor (Figure 6B).
We then tested whether spatially specific perturbation of
AMPK signaling yields this phenotype. Since mitochondria play
a crucial role in ATP synthesis, we hypothesized that perturba-
tion of AMPK signaling at the mitochondria affects intracellular
ATP levels. Therefore, we developed mitochondria-specific AIP
(mito-mChF-AIP) (Figure S7A). Likewise, we designed Golgi
apparatus-specific AIP (Golgi-mChF-AIP) as a control for mito-
mChF-AIP (Figure S7A). We ensured their localization in WT
MEFs using the appropriate organelle markers (Figure S7B). To
examine the inhibitory effect of these organelle-specific AIPs,
we transiently expressed these constructs in WT MEFs with
the appropriate osABKAR. Mito-ABKAR and Golgi-ABKAR
showed that mito-mChF-AIP and Golgi-mChF-AIP suppressed
AMPK activity at the mitochondria (29.4% ± 32% decrease in
WT MEFs) (Figure 6C) and Golgi apparatus (18.7% ± 20.4%
decrease in WT MEFs) (Figure 6D), respectively. These organ-
elle-specific AIPs did not affect overall AMPK activity, as judged
by cytosolic ABKAR, indicating that the inhibitory effect of mito-
mChF-AIP and Golgi-mChF-AIP was confined to mitochondria
and Golgi apparatus, respectively (Figures S7C and S7D).
We next examined the effect of the subcellular compartment-
specific perturbation of AMPK signaling on the intracellular ATP
level. WT MEFs expressing mito-mChF-AIP exhibited a 1.25 ±
0.39-fold increase of intracellular ATP, as shown using the ATP
biosensor (Figure 6E). On the other hand, WT MEFs expressing
Golgi-mChF-AIP did not show any change in intracellular ATP
levels (1.06 ± 0.37-fold) (Figure 6F). Mito-mChF-AIP and Golgi-
mChF-AIP expression did not affect intracellular ATP levels in
DKOMEFs (Figures S7E and S7F). Taken together, these results
suggested that spatio-specific perturbation of AMPK signaling
could both qualitatively and quantitatively reproduce the pheno-
type that we observed by overall AMPK inhibition, implying that
AMPK inhibition at mitochondria is primarily responsible for the
ATP homeostasis in cells.(E) Reconstituted AMPK activity at mitochondria. AMPK activity at mitochondria i
n = 36), mChF-AMPK a1 (WT a1, n = 46; DKO a1, n = 37), or mChF-AMPK a2 (W
(F) Reconstituted AMPK activity at lysosome. AMPK activity at lysosome in cells e
mChF-AMPK a1 (WT a1, n = 44; DKO a1, n = 36), or mChF-AMPK a2 (WT a2, n
*p < 0.05, **p < 0.01, ***p < 0.001.Spatiotemporal Regulation of AMPK Activity at Specific
Subcellular Compartments
The chemically inducible dimerization (CID) system is a powerful
tool to rapidly manipulate spatiotemporal information of target
molecules in cells (DeRose et al., 2013). We therefore examined
whether AIP is able to regulate AMPK activity in differential sub-
cellular compartments on a timescale of seconds by employing
the CID system. Here, a chemical dimerizer like rapamycin in-
duces striking concentration of diffusive FKBP-fused protein
such as mChF-AIP exclusively to one of the organelle surfaces
within seconds (Figure 7A). In the following experiments, we
transiently transfected mChF, mChF-AIP, or mChF-AIP (TA) in
HEK293 epithelial cells together with a mitochondria-anchored
FRB (Tom20-CFP-FRB), then monitored AMPK activity at
mitochondria using mito-ABKAR before and after rapamycin
addition.
While the expression of mChF-AIP slightly suppressed basal
AMPK activity at mitochondria, neither mChF nor mChF-AIP
(TA) exhibited this inhibition (Figure 7B). As expected, mChF
translocation to mitochondria did not affect AMPK activity at
the mitochondria (6.2% ± 7.8% decrease, n = 39, 30 min) (Fig-
ures 7C and 7D). However, translocation of mChF-AIP and
mChF-AIP (TA) to mitochondria resulted in significant de-
creases of AMPK activity at the mitochondria (16.5% ± 9.8%
decrease, n = 35 and 20.4% ± 23.3% decrease, n = 34,
respectively) (Figures 7C and 7D). It is notable that AIP (TA)
indicated very effective suppression of AMPK activity despite
its little to no effect on the kinase prior to its translocation to
the mitochondria. Conversely, WT AIP requires precautions in
this usage in cells due to the background effect. These results
suggest that AIP (TA) is a powerful tool to rapidly and inducibly
perturb AMPK signaling at a specific subcellular compartment.
As these rapidly inducible experiments reproduced the earlier
result obtained with constitutive inhibition of AMPK using
mito-mChF-AIP, we may exclude the possibility that the
Mito-ABKAR FRET signal decreased due to AMPK downregu-
lation triggered by the chronic accumulation of an AMPK
substrate (i.e., AIP) at mitochondria, rather than the direct
competition for AIP.
DISCUSSION
Fluorescent biosensors that can monitor signaling events in
living cells have become an indispensable tool for gaining deeper
insights into spatiotemporally dynamic signal transduction. Here
we designed, characterized, and implemented a series of AMPK
biosensors specifically targeted to individual organelles (osAB-
KAR) to measure AMPK activity at designated subcellular re-
gions of interest. In the present study, we found the unique
osABKAR FRET signals distinctly changing in an AMPK-depen-
dent manner at each subcellular location, revealing that AMPK
activity at the membranes was higher than that in the cytosoln cells expressing Mito-ABKAR and either mChF (WT Cont, n = 56; DKO Cont,
T a2, n = 46; DKO a2, n = 38) was analyzed.
xpressing Lyso-ABKAR and either mChF (WT Cont, n = 52; DKO Cont, n = 28),
= 37; DKO a2, n = 24) was analyzed.
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Figure 5. Development of Genetically Encoded AMPK Inhibitor Peptide
(A) The amino acid sequence alignment of AIP and AIP (TA) is shown.
(B) Inhibitory effect of AIP as judged by in vitro AMPK activity assay. Purified activated AMPK and GST-SAMS were incubated with indicated concentration of
either AIP or AIP (TA). Representative autoradiography image of phosphorylated GST-SAMS is shown.
(C) Data of in vitro AMPK activity assay performed in (B) are presented as mean ± SD. Quantification was performed on three independent experiments.
(D) Inhibitory effect of AIP as judged by ABKAR. Cos7 cells expressing ABKAR and eithermChF (n = 15), mChF-AIP (n = 10), ormChF-AIP (TA) (n = 11) were treated
with 10 mM 2-DG; (left) mean of normalized FRET/CFP ratio ± SD; (right) mean of last five frames (surrounded by a dotted line) ± SD. ***p < 0.001. 15 s/frame.
(E) Representative pseudocolor images of FRET/CFP ratio in cells expressing either mChF or mChF-AIP are shown.
(F) Inhibitory effect of AIP according to western blot assay. WT MEFs transiently transfected with either mChF or mChF-AIP were treated with or without 2-DG.
Subsequently, western blot was performed to determine the phosphorylation level of ACC and AMPK; (left) representative western blot; (right) quantified
phosphorylation level of ACC under indicated condition. Phosphorylation level of ACC was normalized to the non-treated cells expressing mChF. Data are
presented as mean ± SE from three independent experiments. *p < 0.05.under both basal and nutrient-rich conditions. That AMPK is able
to associate with endomembrane (Mitchelhill et al., 1997; Oakhill
et al., 2010) at least partially explains why AMPK activity is666 Cell Reports 11, 657–670, April 28, 2015 ª2015 The Authorsbasally higher in membrane-bound organelles. In apparent
contrast, Golgi-specific Brefeldin A resistance factor 1, which lo-
calizes to Golgi apparatus, was barely phosphorylated by AMPK
even under nutrient-rich conditions (Miyamoto et al., 2008; Mo-
rohashi et al., 2010), as its phosphorylation level increases in
response to ATP depletion (Miyamoto et al., 2008) or during
mitosis (Mao et al., 2013; Morohashi et al., 2010). This prelimi-
nary phosphorylation of AMPK substrates at the organelle
membranes might facilitate execution of AMPK-mediated acute
responses to transient changes in environmental factors.
The glycolysis pathway plays an essential role in ATP synthe-
sis. Both glucose starvation and 2-DG treatment caused meta-
bolic perturbation at the first step of glycolysis, followed by a
decrease in the intracellular ATP level. Since ATP is an essential
molecule for virtually all cellular processes, the intracellular ATP
level is tightly controlled by AMPK (Hardie, 2011). We found that
a different input signal, glucose starvation or 2-DG simulation,
led to distinct patterns of signal propagation to increase
AMPK activity in a subcellular location-dependent manner.
The molecular mechanism of this difference induced by these
seemingly similar metabolic perturbations is not clear, but one
speculation would be that the perturbations result in different
metabolite profiles (Sandulache et al., 2011), which in turn
may be translated into AMPK activity at different subcellular lo-
cations. Alternatively, LKB1 may involve input-dependent
AMPK activation at each organelle in response to these input
stimuli. Interestingly, in agreement with a previous report
(Tsou et al., 2011), glucose starvation and 2-DG treatment did
not increase AMPK activity in the nucleus even under prolonged
treatment. Given that other pharmacological AMPK activators
are able to increase AMPK activity at specific subcellular loca-
tions, including the nucleus (Kodiha et al., 2011; Tsou et al.,
2011), additional input signals could be required to promote
AMPK activation in the nucleus under the metabolically per-
turbed conditions we examined. Taken together, we speculate
that AMPK continuously processes a multitude of input signals
to make appropriate decisions among which are changes in
gene expression, enzymatic activity, and rewiring of their
signaling networks. Future studies may reveal the interplay be-
tween the spatiotemporally dynamic AMPK activity and its
downstream cell functions.
One protein complex could play multiple roles by changing
the number and/or members of its modular constituents.
AMPK is a heterotrimeric complex, composed of a, b, and g
subunits (Shackelford and Shaw, 2009). Given the multiple
subfamily members for each AMPK subunit, 12 different heter-
otrimeric enzymes are theoretically possible. However, the
mechanism of functional distinctions among these AMPK com-
plexes remains unknown. Here we showed that a subunits can
rescue AMPK activity at individual organelles of DKO MEF
cells, but the recovery efficiency varied depending on the
type of a subunit as well as the compartment. This finding im-
plies, among others, that a1- and a2-containing AMPK com-
plexes may be differentially regulated and may thus regulate
separate downstream effectors. While this notion does not
contradict the observation of different phenotypes between
a1 and a2 knockout mice (Viollet et al., 2009), we observed little
to no accumulation of the AMPK a subunit at organelle sur-
faces, contrary to our prediction. Future studies are therefore
necessary to resolve the molecular mechanism underlying
these observations.It was mechanistically insightful to learn that, while both AIP
and AIP (TA) peptides were able to perturb AMPK signaling
when accumulated at mitochondria, only AIP (TA) exhibited
a negligible background inhibition prior to accumulation. The
difference appears to be logically explained by the shifted
dose-response curves obtained from the in vitro kinase assay
(Figure 5C). This speculation further suggests that WT AIP
could readily become a useful tool after optimizing its expres-
sion level in cells. In theory, a concurrent usage of AIP and AIP
(TA) should allow us to manipulate AMPK activity at two
different subcellular locations. While assessment of off-target
inhibition by AIP should be performed, our results collectively
suggest that genetically encoded AIP is a valuable tool to
inhibit AMPK specifically at an intended subcellular location.
Future studies may enable the precise control of cellular func-
tions through the manipulation of AMPK activity at specific
subcellular locations.
In conclusion, we have designed and characterized a geneti-
cally encoded organelle-specific FRET-based biosensor, osAB-
KAR, providing a real-time readout of AMPK activity exclusively
at intended subcellular locations in a native context. Further-
more, we developed a genetically encoded competitive AMPK
inhibitor, AIP, which enables perturbation of AMPK signaling at
specific cellular locations within minutes. A pair of these molec-
ular sensors and actuators offers a platform to disentangle com-
partmentalized AMPK signaling under both physiological and
pathological conditions. Not only the knowledge obtained with
these molecular tools, but also the tools themselves to harness
the dynamic AMPK activity, may eventually lead to novel insights
into the treatment and/or cure of cancers and diabetes where
AMPK regulation has gone awry.EXPERIMENTAL PROCEDURES
Detailed experimental procedures are provided in the Supplemental Experi-
mental Procedures.
Plasmid Construction
The osABKAR was generated by fusing organelle-targeting signal with AB-
KAR. Details regarding osABKAR and other constructs used here are provided
in the Supplemental Experimental Procedures. All constructs were verified by
sequence after subcloning.
Live-Cell Imaging
Cells plated on cover glass were subjected to the live-cell imaging. For imaging
under nutrient-rich condition, DMEM containing 25 mM HEPES, 25 mM
glucose, and 2 mM glutamine (Gibco) was used. For imaging with cells under
glucose starvation and 2-DG treatment, phenol red-free glucose withdrawal
medium (Gibco) and 10 mM 2-DG containing DMEM (25 mM HEPES,
25 mM glucose, and 2 mM glutamine) were used. For Compound C treatment,
cells expressing AMPK biosensor were treated with 40 mM Compound C for
30 min before imaging.
Fluorescent images were obtained using epifluorescence microscopy. De-
tails regarding microscope setting are provided in the Supplemental Experi-
mental Procedures. For time-lapse imaging, fluorescence images were taken
every 15 s for 20 min. Images were normally collected for 5 min before the
addition of 2-DG, and then were collected for 15 min after addition of the
drug. FRET between CFP and YFP was normalized to the mean of the reading
for the first five time points. Mean was calculated from three to four indepen-
dent experiments. Details regarding measurement of intracellular pH are pro-
vided in the Supplemental Experimental Procedures.Cell Reports 11, 657–670, April 28, 2015 ª2015 The Authors 667
Figure 6. Manipulation of Intracellular ATP Level by Subcellular Compartment-Specific AMPK Signaling Perturbation
(A) ATP biosensor was transiently transfected inWTMEFs (n = 40) andDKOMEFs (n = 34); 48 hr after transfection, intracellular ATP level wasmeasured from three
independent experiments. Analyzed FRET/CFP ratio was normalized to the data obtained from WT MEFs. Quantification was performed on three independent
experiments. Data are presented as mean ± SD. **p < 0.01.
(B) The effect of AIP on intracellular ATP level. Cytosolic ATP level in cells expressing either mChF (WT, n = 27; DKO, n = 40), mChF-AIP (WT, n = 29; DKO, n = 40),
or mChF-AIP (TA) (WT, n = 20; DKO, n = 36) was measured under nutrient-rich conditions. ATP level was normalized to that of WT MEFs expressing mChF.
Quantification was performed on three independent experiments. Data are presented as mean ± SD.
(C) The effect of mito-mChF-AIP on AMPK activity at mitochondria. WTMEFs or DKOMEFs were transiently transfected with either mito-mChF (WT, n = 40; DKO,
n = 27) or mito-mChF-AIP (WT, n = 34; DKO, n = 20), then AMPK activity was measured at the mitochondria under nutrient-surplus condition. Quantification was
performed on three independent experiments. Data are presented as mean ± SD.
(D) The effect of Golgi-mChF-AIP on AMPK activity at Golgi apparatus. WT MEFs or DKOMEFs were transiently transfected with either Golgi-mChF (WT, n = 64;
DKO, n = 40) or Golgi-mChF-AIP (WT, n = 43; DKO, n = 29), then AMPK activity wasmeasured at Golgi apparatus under nutrient-surplus condition. Quantification
was performed on three independent experiments. Data are presented as mean ± SD.
(legend continued on next page)
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Figure 7. Spatiotemporal Regulation of
AMPK Activity by CID System
(A) Schematic diagram of CID system. Since
cells express anchor protein, Tom20-CFP-FRB
(Tom20-CR), diffusive FKBP-fused peptide
(mChF-AIP) (left) was trapped at mitochondria in
the presence of rapamycin (right).
(B) The effect of AIP and AIP (TA) on AMPK activity
at mitochondria. HEK293 cells were transiently
transfected with mito-ABKAR; Tom20-CR as an-
chor protein; and either mChF (n = 39), mChF-AIP
(n = 35), or mChF-AIP (TA) (n = 34). Subsequently,
AMPK activity at mitochondria was monitored
before adding rapamycin. *p < 0.05. N.S., statis-
tically nonsignificant.
(C) Inhibitory effect of sequestered AIP at mito-
chondria on AMPK activity. AMPK activity at
mitochondria in HEK293 cells described in (B) was
monitored before (0 min) and after adding rapa-
mycin at each time point. AMPK activity at each
time point was normalized to that at 0 min. Data
are presented as normalized mean ± SD from two
independent experiments. ***p < 0.001.
(D) Representative images of (C) are shown ([top]
FRET/CFP and [bottom] mCherry). Scale bar rep-
resents 10 mm.Statistical Analysis
Statistical analysis was done with an unpaired two-tailed Student’s t test.
F test was used to determine whether variances were equal or not.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, seven figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.celrep.2015.03.057.(E) The effect of mito-mChF-AIP on intracellular ATP level. WT MEFs were transie
ATP level was measured in cytosol by ATP biosensor. Quantification was perfor
(F) The effect of Golgi-mChF-AIP on intracellular ATP level. WTMEFswere transien
ATP level was measured in cytosol by ATP biosensor. Quantification was perfor
**p < 0.01. N.S., statistically nonsignificant.ACKNOWLEDGMENTS
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